Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

IVVD

Invivyd (IVVD)

Invivyd Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:IVVD
日付受信時刻ニュースソース見出しコード企業名
2025/01/1021 : 08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2025/01/1021 : 01GlobeNewswire Inc.Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XECNASDAQ:IVVDInvivyd Inc
2024/12/2806 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/12/0305 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/11/1423 : 16Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IVVDInvivyd Inc
2024/11/1421 : 24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
2024/11/1421 : 19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/11/1421 : 05GlobeNewswire Inc.Invivyd Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:IVVDInvivyd Inc
2024/11/1421 : 01GlobeNewswire Inc.Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the EditorNASDAQ:IVVDInvivyd Inc
2024/11/1222 : 30GlobeNewswire Inc.Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRNASDAQ:IVVDInvivyd Inc
2024/11/0622 : 01GlobeNewswire Inc.Invivyd to Participate in the Guggenheim Securities Healthcare Innovation ConferenceNASDAQ:IVVDInvivyd Inc
2024/11/0621 : 01GlobeNewswire Inc.Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024NASDAQ:IVVDInvivyd Inc
2024/10/2920 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/10/2920 : 03GlobeNewswire Inc.Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term ProfitabilityNASDAQ:IVVDInvivyd Inc
2024/10/2920 : 01GlobeNewswire Inc.Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent ParticipantsNASDAQ:IVVDInvivyd Inc
2024/10/1620 : 01GlobeNewswire Inc.Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024NASDAQ:IVVDInvivyd Inc
2024/10/0120 : 01GlobeNewswire Inc.Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity DataNASDAQ:IVVDInvivyd Inc
2024/09/2320 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/09/2320 : 01GlobeNewswire Inc.Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)NASDAQ:IVVDInvivyd Inc
2024/09/1220 : 01GlobeNewswire Inc.Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19NASDAQ:IVVDInvivyd Inc
2024/09/0622 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/09/0520 : 01GlobeNewswire Inc.Invivyd to Participate in Upcoming Investor ConferencesNASDAQ:IVVDInvivyd Inc
2024/09/0420 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/09/0420 : 01GlobeNewswire Inc.Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™NASDAQ:IVVDInvivyd Inc
2024/09/0320 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/09/0320 : 01GlobeNewswire Inc.Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of InterestNASDAQ:IVVDInvivyd Inc
2024/08/2721 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
2024/08/2720 : 01GlobeNewswire Inc.Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical TrialNASDAQ:IVVDInvivyd Inc
2024/08/1421 : 25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IVVDInvivyd Inc
2024/08/1421 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IVVDInvivyd Inc
 Showing the most relevant articles for your search:NASDAQ:IVVD

最近閲覧した銘柄